The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line rilvegostomig (R) + chemotherapy (CTx) in advanced biliary tract cancer (BTC): Updated analysis of GEMINI-Hepatobiliary substudy 2 cohort A.
 
Jian Zhou
Consulting or Advisory Role - AstraZeneca; MSD
Research Funding - Akeso-Sino Pharma Co., Ltd. (Inst); AstraZeneca (Inst); BeiGene (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); Eddingpharm (Suzhou) Co., Ltd. (Inst); Eisai China Inc. (Inst); Fosun Pharma (Inst); Gilead Sciences (Inst); Innovent Biologics (Inst); Jiangsu Hengrui Medicine (Inst); Junshi Biosciences (Inst); MSD (Inst); OriCell Therapeutics Co.,Ltd. (Inst); Qilu Pharmaceutical (Inst); Roche (Inst); Singlera genomics (Inst); Suzhou Zelgen Biopharmaceuticals Co., Ltd. (Inst)
 
Hye Jin Choi
Consulting or Advisory Role - AstraZeneca; MSD Oncology
 
Masafumi Ikeda
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Exact Sciences; Guardant Health; Incyte; MSD; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Delta-Fly Pharma; Eisai; GlaxoSmithKline; Guardant Health; MSD; Nihon Medi-Physics; Novartis; Ono Yakuhin; Rakuten Medical Japan; Roche; SERVIER
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst)
 
Angela Lamarca
Honoraria - Advanced Accelerator Applications; Advanz Pharma; AstraZeneca; Eisai; Incyte; Ipsen; Jazz Therapeutics; Merck; MSD Oncology; Novartis; Pfizer; QED Therapeutics; Roche; Servier; Taiho Oncology
Consulting or Advisory Role - Albireo Pharma; AstraZeneca/MedImmune; Boehringer Ingelheim; Boston Scientific; EISAI; GENFIT; Ipsen; MSD Oncology; Nutricia; QED Therapeutics; Roche; SERVIER; Taiho Pharmaceutical; TransThera Biosciences
Research Funding - Albireo Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); GENFIT (Inst); Ipsen; Jazz Therapeutics (Inst); Merck (Inst); Novartis (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); Roche (Inst); SERVIER (Inst); Taiho Oncology (Inst); TransThera Biosciences (Inst)
Travel, Accommodations, Expenses - Abbott Nutrition; Advanced Accelerator Applications; Advanz Pharma; Bayer; Celgene; Delcath Systems; Ipsen; Mylan; Novartis; Pfizer; Roche; Sirtex Medical
 
Do-Youn Oh
Consulting or Advisory Role - Abbvie; Alligtor Bioscience AB; Arcus Biosciences; ASLAN Pharmaceuticals; Astellas Pharma; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Eutilex; Genentech/Roche; Halozyme; Hana Pharm; Hanmi; Idience; IQVIA; J-Pharma; LG Chem; Merck Serono; Mirati Therapeutics; Moderna Therapeutics; MSD Oncology; Novartis; Revolution Medicines; Taiho Pharmaceutical; Tallac Therapeutics; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Hanmi; Lilly; MSD; Novartis; SERVIER
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Ying-Chun Shen
Honoraria - AstraZeneca; Bristol-Myers Squibb; Ipsen; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Roche
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Ipsen; Ono Pharmaceutical; Roche
Research Funding - Ipsen (Inst)
 
Hong Jae Chon
Honoraria - AstraZeneca; BeiGene; Boryung; Bristol Myers Squibb; Eisai; MSD; Ono Pharmaceutical; Roche; Sanofi; Servier
Consulting or Advisory Role - Aptamer Science; AstraZeneca; BeiGene; Boryung; Bristol Myers Squibb; Eisai; IMBDx; MSD; Ono Pharmaceutical; Roche; Servier
Research Funding - BeiGene; Boryung; Dong-A ST; IMBDx; Roche
 
Hyung-Don Kim
Honoraria - AstraZeneca/MedImmune; Boostimmune; Boryung Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo; MSD; Ono Pharmaceutical
Consulting or Advisory Role - Mustbio
Research Funding - Amgen; BeOne; Roche/Genentech/Foundation Medicine
 
Tiziana Pressiani
Consulting or Advisory Role - AstraZeneca; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Roche
 
Andrea Casadei Gardini
No Relationships to Disclose
 
Ruifan Xie
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Rui Miao
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Mingchao Xie
Employment - AstraZeneca
 
Huizhong Hu
Employment - AstraZeneca
 
Mengzhu Wang
Employment - AstraZeneca
 
Olivia Aoli
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Blue Wu
Employment - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Jennifer Yang
Employment - AstraZeneca
 
Ghassan Abou-Alfa
Consulting or Advisory Role - Abbvie; Ability Pharma (I); Agenus (I); Alligator Bioscience (I); Amgen (I); Arcus Ventures (I); Astellas Pharma (I); Astellas Pharma (I); AstraZeneca; Autem Medical; Berry Genomics; BioNtech (I); Boehringer Ingelheim (I); Bristol-Myers Squibb/Medarex (I); Fibrogen (I); Ikena Oncology (I); Immuneering (I); Ipsen; J-Pharma; Merck Serono (I); Merus NV (I); Moma Therapeutics (I); Neogene Therapeutics (I); Novartis (I); Regeneron (I); Revolution Medicines (I); Roche/Genentech; Servier; Syros Pharmaceuticals (I); Tango Therapeutics (I); Tempus (I); Vector Health; Yiviva
Research Funding - Abbvie (Inst); Agenus (Inst); Amgen (Inst); Arcus Ventures (Inst); AstraZeneca (Inst); Atara Biotherapeutics (Inst); Beigene (Inst); BioNtech (Inst); Bristol-Meyer Squibb (Inst); Bristol-Myers Squibb (Inst); Coherus Biosciences (Inst); Digestive Care (Inst); Elicio Therapeutics (Inst); Genentech/Roche (Inst); Helsinn Healthcare (Inst); J-Pharma (Inst); Revolution Medicines (Inst); Yiviva (Inst)